An Advancement in Regenerative Medicine
Amniotic tissue and stem cell advancements offer a unique opportunity for healing using minimally invasive techniques for pain management. In this practice, they are used with application in orthopedics, pain management as well as Aesthetic medicine.
Common orthopedic injuries treated with allograft tissues: all joints and spine: Shoulder, elbow, wrist, hip, knee, ankle
- Tendon injuries
- Ligament injuries
- Joint and cartilage disorders
- Advances osteoarthritis
- Plantar Fasciitis
- Meniscal tears, labrum tear and ACL and PCL tears
- Soft tissues injury
What is Amniotic Fluid Allograft ?
Fluid Flow (Tm) is a unique amniotic liquid allograft used to accelerate soft-tissue repair, replacement, and reconstruction. It’s currently being used successfully address degenerative joint disorders, inflammatory conditions, and soft-tissue injuries.
What is Amniotic Fluid Allograft Made of ?
Liquid allograft is derived from human amniotic fluid. It is rich in natural growth factors, cytokines, and proteins associated with tissue repair, replacement and regeneration.
- The growth factors which stimulate cellular growth and differentiation via epidermal growth factor, platelet derived growth factor, and transforming growth factor-Beta 1.
- The Growth factors which stimulate tissue remodeling are Matrix Metallopeptidases 9, MMP-9,
- The Growth factors which have anti -inflammatory activity- IL-10, Interleukin 10, IL -1Ra, Interleukin- 1 receptor antagonist
- The Growth factors which have anti -microbial activity- MPO Myeloperoxidase
- 100% free of the lyophilized or micronized membrane. This is Terminally sterilized.
Key Benefits of Amniotic Fluid:
- Reduces scar tissue, anti-fibrotic
- Contains essential growth factors to induce healing
Safety & Quality: Allograft products preserve the placenta and fluid, which are typically discarded. All tissues obtained with aseptic techniques are then tested to ensure viability and safety. The tissue is taken from prescreened patients against infectious disease. The allografts are subjected to stringent USP testing prior to release.